A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

Name: A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Published: 2021
License: Public Domain

Novartis Pharmaceuticals · 2021

ClinicalTrials.gov · Datasets · License: Public Domain · 2021

Open Source ↗

chronic-kidney-disease egfr glomerulonephritis

primary iga nephropathy, immunoglobulin a nephropathy, igan, chronic kidney disease, glomerulonephritis, complement alternative pathway, egfr, upcr, uacr, lnp023, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

Related documents